ReviewJournal of physiology and biochemistry2025
Long non-coding RNA NR2F1-AS1: an increasingly significant LncRNA in human cancers.
Review in Journal of physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- lncRNACancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs), defined as transcripts exceeding 200 nucleotides without protein-coding potential, have emerged as pivotal regulators in diverse physiological and pathological processes, particularly in tumorigenesis. Among them, NR2F1-AS1, a recently characterized lncRNA, has garnered growing attention due to its dysregulated expression across a spectrum of malignancies and its significant correlation with key clinicopathological parameters. Accumulating evidence from molecular and cellular studies reveals that NR2F1-AS1 plays multifaceted roles in cancer initiation and progression through the modulation of signaling pathways, regulation of gene expression, and interactions with microRNAs and protein complexes. Notably, its biological function appears to be context-dependent: acting as an oncogene in many cancer types, such as breast, lung, liver, and gastric cancer, while exhibiting potential tumor-suppressive activity in others, including colorectal cancer, cervical squamous cell carcinoma, and thymic epithelial tumors. This review comprehensively summarizes the aberrant expression patterns, prognostic significance, biological functions, and molecular mechanisms of NR2F1-AS1, while also highlighting its emerging potential as a context-specific diagnostic biomarker and therapeutic target in human cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.